• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较基于代谢功能障碍相关脂肪性肝病和非酒精性脂肪性肝病的糖尿病预测:ELSA-Brasil 研究。

Comparing diabetes prediction based on metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease: the ELSA-Brasil study.

机构信息

Programa de Pós-graduação em Epidemiologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil.

Departamento de Estatística, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil.

出版信息

Cad Saude Publica. 2024 Nov 25;40(11):e00009924. doi: 10.1590/0102-311XEN009924. eCollection 2024.

DOI:10.1590/0102-311XEN009924
Abstract

We aimed to compare nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) definitions concerning diabetes prediction in a large sample of Brazilian adults. As a secondary objective, we compared associations between NAFLD/MASLD and diabetes across self-declared race/skin color groups. The Brazilian Longitudinal Study of Adult Health (ELSA-Brasil) is a prospective cohort study of Brazilian civil servants (35-74 years) enrolled from 2008 to 2010 and followed up from 2012-2014 and 2017-2019. We ascertained type 2 diabetes mellitus at baseline as well as follow-up visits based on self-reported diagnosis, medication use, and glycemic tests (fasting and 2h post-OGTT glucose and HbA1c). We excluded individuals with heavy alcohol consumption or self-reported cirrhosis/hepatitis. We analyzed 7,073 subjects. NAFLD was defined by ultrasound-based steatosis. Participants with steatosis and at least one cardiometabolic factor were considered as having MASLD. Cox proportional hazards models were performed to evaluate the association between NAFLD/MASLD and the incidence of type 2 diabetes mellitus. At baseline, 33.9% of individuals presented NAFLD and 32.5% presented MASLD. Over 9.4 years of follow-up, the relative increase in the incidence of diabetes was 78% for NAFLD (HR = 1.78; 95%CI: 1.58-2.01) and 88% for MASLD (HR = 1.88; 95%CI: 1.67-2.12). Associations did not differ significantly among race/skin color groups (p for interaction = 0.10 for MASLD and 0.08 for NAFLD). In this large cohort of middle-aged and older Brazilian adults, the relative incidence of diabetes was similar for NAFLD and MASLD definitions, with similar associations in all ethnic groups.

摘要

我们旨在比较非酒精性脂肪性肝病(NAFLD)和代谢功能障碍相关脂肪性肝病(MASLD)的定义,以评估其在巴西成年人大型样本中对糖尿病的预测价值。次要目标是比较 NAFLD/MASLD 与糖尿病在自我报告的种族/肤色组之间的关联。巴西纵向成人健康研究(ELSA-Brasil)是一项对巴西公务员(35-74 岁)进行的前瞻性队列研究,研究对象于 2008 年至 2010 年招募,随访时间为 2012-2014 年和 2017-2019 年。我们根据自我报告的诊断、药物使用和血糖测试(空腹和口服葡萄糖耐量试验后 2 小时血糖和 HbA1c)在基线和随访时确定 2 型糖尿病。排除有大量饮酒或自我报告的肝硬化/肝炎的个体。共纳入 7073 名参与者。NAFLD 通过超声检查确定脂肪变性。存在脂肪变性和至少一种心血管代谢因素的参与者被认为患有 MASLD。采用 Cox 比例风险模型评估 NAFLD/MASLD 与 2 型糖尿病的发生率之间的关联。基线时,33.9%的个体患有 NAFLD,32.5%的个体患有 MASLD。在 9.4 年的随访期间,NAFLD 的糖尿病发病率相对增加了 78%(HR=1.78;95%CI:1.58-2.01),MASLD 的糖尿病发病率相对增加了 88%(HR=1.88;95%CI:1.67-2.12)。在不同种族/肤色组之间,这些关联没有显著差异(MASLD 的交互作用 P 值=0.10,NAFLD 的交互作用 P 值=0.08)。在这个巴西中年和老年成年人的大型队列中,NAFLD 和 MASLD 定义的糖尿病相对发病率相似,在所有种族群体中均具有相似的关联。

相似文献

1
Comparing diabetes prediction based on metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease: the ELSA-Brasil study.比较基于代谢功能障碍相关脂肪性肝病和非酒精性脂肪性肝病的糖尿病预测:ELSA-Brasil 研究。
Cad Saude Publica. 2024 Nov 25;40(11):e00009924. doi: 10.1590/0102-311XEN009924. eCollection 2024.
2
Metabolic dysfunction-associated steatotic liver disease: A superior predictor for incident type 2 diabetes over traditional criteria - NAGALA study.代谢功能障碍相关脂肪性肝病:相较于传统标准,对2型糖尿病发病的更优预测指标——NAGALA研究
J Diabetes Investig. 2024 Dec;15(12):1788-1796. doi: 10.1111/jdi.14315. Epub 2024 Sep 16.
3
Liver steatosis as a predictor of incident diabetes in adults: a prospective evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).肝脂肪变性作为成年人新发糖尿病的预测因子:巴西成人健康纵向研究(ELSA-Brasil)的前瞻性评估。
Cad Saude Publica. 2023 Mar 1;39(3):e00090522. doi: 10.1590/0102-311XEN090522. eCollection 2023.
4
Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.代谢相关脂肪性肝病和非酒精性脂肪性肝病的临床特征和病死率相似。
J Hepatol. 2024 May;80(5):694-701. doi: 10.1016/j.jhep.2024.01.014. Epub 2024 Jan 27.
5
Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study.心脏代谢指标与代谢功能障碍相关脂肪性肝病的发病及其向肝纤维化进展之间的关联:一项队列研究
Cardiovasc Diabetol. 2025 Apr 3;24(1):154. doi: 10.1186/s12933-025-02716-6.
6
Prognostic value of metabolic dysfunction-associated steatotic liver disease over coronary computed tomography angiography findings: comparison with no-alcoholic fatty liver disease.代谢相关脂肪性肝病与冠状动脉 CT 血管造影结果的预后价值比较:与非酒精性脂肪肝的比较。
Cardiovasc Diabetol. 2024 May 10;23(1):167. doi: 10.1186/s12933-024-02268-1.
7
Type 2 Diabetes and Hypertension as Risk Factors for Advanced Fibrosis in Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease.2型糖尿病和高血压作为活检证实的代谢功能障碍相关脂肪性肝病中晚期肝纤维化的危险因素。
J Dig Dis. 2024 Nov-Dec;25(11-12):685-693. doi: 10.1111/1751-2980.13325. Epub 2025 Jan 13.
8
Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.隐匿性脂肪性肝病患者的肝脏与动脉粥样硬化风险。
Hepatol Int. 2024 Jun;18(3):943-951. doi: 10.1007/s12072-023-10624-8. Epub 2024 Jan 16.
9
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南:代谢功能障碍相关脂肪性肝病(MASLD)的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
10
Comparison of Non-invasive Liver Fat Scoring Systems as Markers of Metabolic Dysfunction-Associated Liver Disease.作为代谢功能障碍相关肝病标志物的非侵入性肝脂肪评分系统比较
Cureus. 2024 Oct 23;16(10):e72222. doi: 10.7759/cureus.72222. eCollection 2024 Oct.

引用本文的文献

1
Impact of steatotic liver diseases on diabetes mellitus risk in patients with atrial fibrillation: a nationwide population study.脂肪性肝病对心房颤动患者糖尿病风险的影响:一项全国性人群研究。
Cardiovasc Diabetol. 2025 Jun 7;24(1):242. doi: 10.1186/s12933-025-02795-5.

本文引用的文献

1
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024.2. 糖尿病的诊断与分类:《2024年糖尿病医疗护理标准》
Diabetes Care. 2024 Jan 1;47(Suppl 1):S20-S42. doi: 10.2337/dc24-S002.
2
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States.美国非酒精性脂肪性肝病患者中不同种族和民族差异及不利健康社会决定因素的作用及其在各亚型中的表现。
Hepatol Commun. 2023 Dec 1;7(12). doi: 10.1097/HC9.0000000000000324.
3
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.
回复:关于新的脂肪性肝病命名的多学会德尔菲共识声明。
Hepatology. 2024 Mar 1;79(3):E93-E94. doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.
4
Changing from NAFLD to MASLD: The new definition can more accurately identify individuals at higher risk for diabetes.从非酒精性脂肪性肝病转变为代谢功能障碍相关脂肪性肝病:新定义能够更准确地识别出糖尿病风险较高的个体。
J Hepatol. 2024 Feb;80(2):e85-e87. doi: 10.1016/j.jhep.2023.09.035. Epub 2023 Oct 10.
5
Changing from NAFLD through MAFLD to MASLD: Similar prevalence and risk factors in a large Brazilian cohort.从非酒精性脂肪性肝病(NAFLD)到代谢相关脂肪性肝病(MAFLD)再到代谢相关脂肪性肝炎(MASLD)的转变:巴西一个大型队列中的相似患病率和风险因素
J Hepatol. 2024 Feb;80(2):e72-e74. doi: 10.1016/j.jhep.2023.08.025. Epub 2023 Sep 9.
6
Liver steatosis as a predictor of incident diabetes in adults: a prospective evaluation in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil).肝脂肪变性作为成年人新发糖尿病的预测因子:巴西成人健康纵向研究(ELSA-Brasil)的前瞻性评估。
Cad Saude Publica. 2023 Mar 1;39(3):e00090522. doi: 10.1590/0102-311XEN090522. eCollection 2023.
7
Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study.非酒精性脂肪性肝病与 2 型糖尿病发病风险的种族差异:来自 CARDIA 研究的结果。
Diabetologia. 2023 Jul;66(7):1235-1246. doi: 10.1007/s00125-023-05903-w. Epub 2023 Mar 21.
8
Trends and predictions of malnutrition and obesity in 204 countries and territories: an analysis of the Global Burden of Disease Study 2019.204个国家和地区营养不良与肥胖的趋势及预测:基于2019年全球疾病负担研究的分析
EClinicalMedicine. 2023 Feb 16;57:101850. doi: 10.1016/j.eclinm.2023.101850. eCollection 2023 Mar.
9
Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019.1990年至2019年204个国家和地区非酒精性脂肪性肝病的全球负担。
Clin Res Hepatol Gastroenterol. 2023 Jan;47(1):102068. doi: 10.1016/j.clinre.2022.102068. Epub 2022 Dec 10.
10
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review.种族和民族在非酒精性脂肪性肝病(NAFLD)中的作用:一项叙述性综述。
Nutrients. 2022 Oct 28;14(21):4556. doi: 10.3390/nu14214556.